SAPPHIRE:西曲替尼联合纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌的III期研究
SAPPHIRE III期研究纳入577例晚期非鳞状非小细胞肺癌患者,这些患者曾从检查点抑制剂(CPI)治疗中获益(≥4个月无进展)后出现疾病进展。患者随机接受西曲替尼联合纳武利尤单抗(sitra+nivo)或多西他赛治疗。主要终点总生存期(OS)未达统计学显著改善:中位OS 12.2 vs 10.6个月(HR 0.86,95%CI 0.70-1.05;P=0.144)。
要点
- sitra+nivo组中位OS为12.2个月,多西他赛组为10.6个月,HR 0.86(95%CI 0.70-1.05;P=0.144),未达统计学显著。
- sitra+nivo组中位PFS为4.4个月,多西他赛组为5.4个月(HR 1.08,95%CI 0.89-1.32;P=0.452)。
- sitra+nivo组≥3级治疗相关不良事件发生率为53.0%,多西他赛组为66.7%。
核心结论
- 尽管sitra+nivo组中位OS在数值上长于多西他赛组,但主要终点未达到。
- 安全性特征与既往报告一致。
研究设计与样本
- III期SAPPHIRE研究,随机、开放标签,纳入577例晚期非驱动基因非鳞状非小细胞肺癌患者。
- 患者随机1:1接受西曲替尼(100 mg每日一次口服)联合纳武利尤单抗(240 mg每2周或480 mg每4周静脉注射)或多西他赛(75 mg/m2每3周静脉注射)。
- 主要终点为总生存期(OS);次要终点包括无进展生存期(PFS)、客观缓解率(ORR)、临床获益率(CBR)、缓解持续时间(DOR)和安全性。
主要发现
- sitra+nivo组(n=284)中位OS为12.2个月,多西他赛组(n=293)为10.6个月;HR 0.86(95%CI 0.70-1.05;P=0.144)。
- sitra+nivo组中位PFS为4.4个月,多西他赛组为5.4个月;HR 1.08(95%CI 0.89-1.32;P=0.452)。
- sitra+nivo组ORR为15.6%,多西他赛组为17.2%(P=0.597);CBR分别为75.5%和64.5%(P=0.004)。
- sitra+nivo组中位DOR为7.4个月,多西他赛组为7.1个月(P=0.924)。
- sitra+nivo组≥3级治疗相关不良事件发生率为53.0%,多西他赛组为66.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Checkpoint inhibitor (CPI) therapy revolutionized treatment for advanced non-small-cell lung cancer (NSCLC); however, most patients progress due to primary or acquired resistance. Sitravatinib is a receptor tyrosine kinase inhibitor that can shift the immunosuppressive tumor microenvironment toward an immunostimulatory state. Combining sitravatinib with nivolumab (sitra + nivo) may potentially overcome initial CPI resistance. PATIENTS AND METHODS: In the phase III SAPPHIRE study, patients with advanced non-oncogenic driven, nonsquamous NSCLC who initially benefited from (≥4 months on CPI without progression) and subsequently experienced disease progression on or after CPI combined with or following platinum-based chemotherapy were randomized 1 : 1 to sitra (100 mg once daily administered orally) + nivo (240 mg every 2 weeks or 480 mg every 4 weeks administered intravenously) or docetaxel (75 mg/m2 every 3 weeks administered intravenously). The primary endpoint was overall survival (OS). The secondary endpoints included progression-free survival (PFS), objective response rate (ORR), clinical benefit rate (CBR), duration of response (DOR; all assessed by blinded independent central review), and safety. RESULTS: A total of 577 patients included randomized: sitra + nivo, n = 284; docetaxel, n = 293 (median follow-up, 17.1 months). Sitra + nivo did not significantly improve OS versus docetaxel [median, 12.2 versus 10.6 months; hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.70-1.05; P = 0.144]. The median PFS was 4.4 versus 5.4 months, respectively (HR 1.08, 95% CI 0.89-1.32; P = 0.452). The ORR was 15.6% for sitra + nivo and 17.2% for docetaxel (P = 0.597); CBR was 75.5% and 64.5%, respectively (P = 0.004); median DOR was 7.4 versus 7.1 months, respectively (P = 0.924). Grade ≥3 treatment-related adverse events were observed in 53.0% versus 66.7% of patients receiving sitra + nivo versus docetaxel, respectively. CONCLUSIONS: Although median OS was numerically longer with sitra + nivo, the primary endpoint was not met in patients with previously treated advanced nonsquamous NSCLC. The safety profiles demonstrated were consistent with previous reports.
引用
- Borghaei H, de Marinis F, Dumoulin D, et al. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2023. PMID: 37866811. doi:10.1016/j.annonc.2023.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。